-
Depositing Lab
-
Sequence Information
Full plasmid sequence is not available for this item.
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 43882 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepUC57
-
Backbone manufacturerGenscript
- Backbone size w/o insert (bp) 2710
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSID4X Domain
-
Alt nameSID domain
-
Alt nameEnhanced Repressor Domain for TAL Effector (SID4X)
-
Alt namemSin Interaction Domain
-
Insert Size (bp)432
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site NheI (not destroyed)
- 3′ cloning site XbaI (destroyed during cloning)
- 5′ sequencing primer pUC57 Forward (GTAAAACGACGGCCAGTG)
- 3′ sequencing primer pUC57 Reverse (GGAAACAGCTATGACCATG) (Common Sequencing Primers)
Resource Information
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This enhanced SID domain (SID4X domain) is to be used with TALE effectors to create TALE repressors, as described in Cong et al. Nature Communications. This new domain replaces the previous SID domain reported in the original article.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Enhanced Repressor Domain for TAL Effector (SID4X) was a gift from Feng Zhang (Addgene plasmid # 43882 ; http://n2t.net/addgene:43882 ; RRID:Addgene_43882) -
For your References section:
Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Cong L, Zhou R, Kuo YC, Cunniff M, Zhang F. Nat Commun. 2012 Jul 24;3:968. doi: 10.1038/ncomms1962. 10.1038/ncomms1962 PubMed 22828628